Aparna Ahuja, MD joined T2 Biosystems as Chief Medical Officer in January of 2021. Dr. Ahuja possesses extensive global experience in laboratory medicine and medical diagnostics. Most recently, she served as Worldwide Vice President, Medical Affairs at Becton Dickinson, where she was responsible for global medical leadership, setting and leading the strategy for medical affairs, clinical development, and key opinion leader engagement in support of new product development, lifecycle management, and compliance. Prior to Becton Dickinson, Dr. Ahuja held a variety of roles in clinical practice, research, and academia where she was focused on continuous improvement and innovation in diagnostics, stressing precision, and rapid turnaround times. A clinical pathologist by training, Dr. Ahuja completed multiple residencies emphasizing medical biochemistry, molecular biology, and laboratory medicine. She earned a Bachelor of Medicine, Bachelor of Surgery, completed her MD Residencies, and received her Postgraduate Diploma in Family Welfare, Child Health, and Hospital Management from Delhi University. A certified auditor with ISO 15189 (NABL) & CAP, Dr. Ahuja has successfully led and guided pathology laboratories through audits and inspections from CAP, ISO 15189, ANVISA, CDC, and the FDA. She is an active member of the American Association of Clinical Chemistry (AACC), College of American Pathologists (CAP), American Society of Microbiology (ASM), European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), and serves as President of AACC New Jersey and as Vice-Chair of CLSI’s Expert Panel.  As an ardent speaker, she presents at renowned International Laboratory Medicine Conferences and has many peer-reviewed publications to her credit.